325 results on '"Yuan, Zhongyu"'
Search Results
52. Effects of Quenching Cooling Rate on Residual Stress and Mechanical Properties of a Rare-Earth Wrought Magnesium Alloy
53. Synaptopodin‐2 suppresses metastasis of triple‐negative breast cancer via inhibition of YAP/TAZ activity
54. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer
55. Lymph Node Ratio and pN Staging Show Different Superiority As Prognostic Predictors Depending on the Number of Lymph Nodes Dissected in Chinese Patients With Luminal A Breast Cancer
56. Mechanism of Magnetic Permeability Perturbation in Magnetizing-Based Eddy Current Nondestructive Testing
57. The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer
58. Abstract P2-13-35: Pyrotinib combined with fulvestrant in women with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A single-arm phase II clinical trial
59. Meta-Analysis Comparing Safety and Efficacy of Left Bundle Branch Area Pacing Versus His Bundle Pacing
60. Epigenetic Inheritance From Normal Origin Cells Can Determine the Aggressive Biology of Tumor-Initiating Cells and Tumor Heterogeneity
61. PAH Pollution and Risk in Particulate Matter in Chinese Cities
62. A Novel Inflammatory-Nutritional Prognostic Scoring System for Patients with Early-Stage Breast Cancer
63. Germline Mutational Profiles and Clinicopathological Features Of Hereditary Breast Cancer In Chinese Population
64. A Thickness Reduction Detection Method Based on Magnetic Permeability Perturbation Under DC Magnetization for Ferromagnetic Components
65. Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: A retrospective matched case–control study
66. Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer
67. A Novel Prognostic Model Based on the Serum Iron Level for Patients With Early-Stage Triple-Negative Breast Cancer
68. An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Breast Cancer
69. Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
70. The diagnostic value of a new formula combining age and prostate volume in prostate cancer
71. The predictive value of the ratio of the product of neutrophils and hemoglobin to lymphocytes in non‐muscular invasive bladder cancer patients with postoperative recurrence
72. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.
73. A phase Ib study of proxalutamide (GT0918) in women with androgen receptor-positive metastatic breast cancer.
74. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens
75. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray
76. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray
77. Characteristics of Chinese male patients with breast cancer: summary of the published papers
78. Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study
79. New classification for advanced breast cancer patients experiencing disease progression during salvage treatment: a single-center retrospective cohort study
80. Cover Image: Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center
81. A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy
82. Concentrations of polycyclic aromatic hydrocarbons in street dust from bus stops in Qingyang city: Estimates of lifetime cancer risk and sources of exposure for daily commuters in Northwest China
83. Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China
84. Cavin3 Suppresses Breast Cancer Metastasis via Inhibiting AKT Pathway
85. Uncovering the Mechanisms of Cryptotanshinone as a Therapeutic Agent Against Hepatocellular Carcinoma
86. Adjuvant chemotherapy for small, lymph node–negative, triple‐negative breast cancer: A single‐center study and a meta‐analysis of the published literature
87. Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer
88. Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).
89. Efficacy and safety of pegfilgrastim in prophylaxis of chemotherapy-induced neutropenia in breast cancer patients.
90. Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center
91. The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer
92. Abstract OT1-04-01: Adjuvant ovarian suppression plus aromatase inhibitor or tamoxifen for hormone receptor-positive breast cancer in women younger than 35 (ASPAIT): A multicenter randomized clinical trial
93. Local treatment for liver oligometastases in breast cancer patients: identification of prognostic factors and exploration of appropriate treatment strategy
94. QiDiTangShen Granules Activate Renal Nutrient-Sensing Associated Autophagy in db/db Mice
95. A Single-Cell Immune Atlas of Triple Negative Breast Cancer Reveals Novel Immune Cell Subsets
96. A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy.
97. Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer
98. A Single-Cell Immune Atlas of Triple Negative Breast Cancer Reveals Novel Immune Cell Subsets
99. Cost-effectiveness of primary prophylaxis with pegfilgrastim in early-stage breast cancer patients receiving chemotherapy in China.
100. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in Chinese population.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.